comprehensive -WSS

comprehensive

author：comprehensive 2025-09-06 04:17:41 - browse：13533

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Novo Nordisk to expand supply of Wegovy for U.S. patients

knowledge

WSS

ARCH Venture Partners is raising $3 billion for a life sciences fund

SAMSHA loosens regulations on methadone treatment centers

FDA drug safety: Singulair case shows systemic surveillance flaws

Juul spent big to court Black leaders to promote its e

SAMSHA loosens regulations on methadone treatment centers

Some dementia cases could be undiagnosed liver disease

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

knowledge

Medicare details structure of new drug price negotiation program

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Inequities make cancer less preventable for women: report

Duchenne breakthrough therapy leaves behind pioneering families

Shingles, which affected Dianne Feinstein, is on the rise

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Covid vaccines: Private market messier than government rollout

Activists slam private health insurers over coverage restrictions

Biogen shutters digital health group, ends Apple study, in cost cutting move

explore

FDA drug safety: Singulair case shows systemic surveillance flaws

Vertex non

ARCH Venture Partners is raising $3 billion for a life sciences fund

Why do women spend more than men on medical expenses?

Covid misinformation case heads to Supreme Court

Paxlovid should be available without a positive Covid test

knowledge

hotspot

hotspot

focus